World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 6.916
Year - 2026
Volume: 5; Issue: 7
Page: 322-345

ANTIMICROBIAL STEWARDSHIP: STRATEGIES, CHALLENGES, AND ROLE OF CLINICAL PHARMACISTS

Dr. M. Anusha*[1], R. Bhargav[2], Peram Navya[3], A. Alekhya[4], M. Nikhitha[5]

[1]Associate Professor, Malla Reddy College of Pharmacy, Maisammaguda, Dhulapally, Kompally (Po) Secunderabad -500100.

[2,3,4]Pharm D fourth Year, Malla Reddy College of Pharmacy, Maisammaguda, Dhulapally, Kompally (Po) Secunderabad -500100.

Article Received: 15 May 2026 || Article Revised: 05 June 2026 || Article Accepted: 26 June 2026

***Corresponding Author: Dr. M. Anusha**
Associate Professor, Malla Reddy College of Pharmacy, Maisammaguda, Dhulapally, Kompally (Po) Secunderabad -500100.
DOI: https://doi.org/10.5281/zenodo.21167114

How to cite this Article: Dr. M. Anusha, R. Bhargav, Peram Navya, A. Alekhya, M. Nikhitha (2026) ANTIMICROBIAL STEWARDSHIP: STRATEGIES, CHALLENGES, AND ROLE OF CLINICAL PHARMACISTS. World Journal of Pharmaceutical Science and Research, 5(7), 322-345.

ABSTRACT

Antimicrobial resistance is a serious worldwide health concern caused by the overuse of antimicrobial agents. Antibiotic Stewardship Programs (ASPs) seek to improve antibiotic therapy, patient outcomes, and resistance development. This study examines key antimicrobial stewardship principles and techniques, as well as clinical pharmacists' contributions to their implementation.[1] It emphasizes measures such as audit and feedback, formulary restriction, dose optimization, de-escalation therapy, and guideline-based prescribing. Artificial intelligence and quick diagnostic methods are among the advances discussed. Successful antimicrobial stewardship requires teamwork among healthcare providers and can result in reduced inappropriate antibiotic usage, cheaper healthcare costs; shorter hospital stays, and decreased resistance. Clinical pharmacists play an important role in promoting rational antibiotic use and improving patient care by implementing evidence-based procedures.[2]

KEYWORDS: Antimicrobial resistance; Antibiotic stewardship; Antimicrobial stewardship program; Clinical pharmacist; Pharmacotherapeutic strategies; Antibiotic misuse; Multidrug resistance; Therapeutic drug monitoring; Infection control; Pharmacokinetics/pharmacodynamics.

INTRODUCTION

Antimicrobial drugs are critical in modern medicine, having greatly reduced morbidity and death from infectious infections since the discovery of penicillin in 1928. They have simplified difficult medical processes and enhanced care; nonetheless, improper use has resulted in antimicrobial resistance (AMR), a major worldwide health problem.

AMR occurs when microbes adapt to treatments, multiplying through genetic changes or gene transfer, and spreading fast, especially in healthcare settings. MRSA, VRE, and multidrug-resistant strains of diverse organisms are among the most common resistant infections.

Over prescription, self-medication, and antibiotic use in agriculture have all contributed to the growth of AMR.[3]

Many drugs are abused for viral infections, and inadequate treatment promotes the survival of resistant strains. This dilemma is compounded by globalization, which allows for the rapid spread of resistant illnesses, posing a challenge to healthcare systems, particularly in low-income nations with limited resources.

Antimicrobial stewardship programs (ASPs) have been formed to prevent AMR by advocating the most effective use of antimicrobial agents through evidence-based procedures. Pharmacotherapeutic techniques that take into account pharmacokinetics and pharmacodynamics are critical for providing effective therapy while reducing toxicity and resistance development. Clinical pharmacists play an important role in these programs by monitoring prescription use, educating patients on appropriate prescribing, and ensuring adherence to standards.[4]

Challenges to ASP implementation include limited resources, a lack of skilled workers, and low public awareness.

Inadequate surveillance and access to antibiotics exacerbate the problems in resource-limited areas. Innovations in molecular diagnostics and artificial intelligence provide new possibilities to improve stewardship efforts. The "One Health" concept emphasizes the importance of comprehensive measures that integrate human, animal, and environmental health to effectively combat AMR. This review discusses the burden of AMR, the reasons of antibiotic abuse, stewardship principles, and future initiatives for its control.[5]

ANTIMICROBIAL RESISTANCE: GLOBALBURDEN

Antimicrobial resistance (AMR) is a major global public health concern that occurs when germs survive exposure to previously effective antimicrobial agents. This resistance complicates infection treatment, resulting in higher mortality and healthcare costs, especially in low- and middle-income countries with poor healthcare infrastructure. In 2019, bacterial AMR was responsible for around 1.27 million direct deaths. Excessive and inappropriate antibiotic use in both healthcare and agriculture contributes to resistance development.[6]

AMR's economic impact could reach levels comparable to severe financial crises by 2050, disproportionately harming underdeveloped countries. MRSA and multidrug-resistant tuberculosis (MDR-TB) are prominent resistant microorganisms that complicate modern medical techniques. To tackle AMR, international collaboration is critical, including tactics such as antimicrobial stewardship, increased surveillance, and investment in innovative treatments, as outlined in the WHO Global Action Plan on Antimicrobial Resistance.[7]

PRINCIPLES OF ANTIMICROBIAL STEWARDSHIP

Antimicrobial stewardship is a systematic method to optimizing the use of antimicrobial drugs in order to improve patient outcomes, minimize antimicrobial resistance (AMR), lower adverse medication reactions, and save healthcare expenditures. Antimicrobial stewardship programs (ASPs) are used in a variety of healthcare settings, including hospitals and clinics, to ensure that antimicrobials are prescribed responsibly. The growing threat of multidrug-resistant pathogens, along with a halt in new antibiotic development, highlight the importance of stewardship in modern healthcare.[8]

The basic goals are to achieve optimal clinical results in infection management, minimize toxicity, reduce the spread of resistant microbes, maintain the efficacy of current antimicrobial medicines, and reduce unnecessary healthcare costs. Effective antimicrobial stewardship requires teamwork among healthcare professionals, including physicians, clinical pharmacists, microbiologists, infection control specialists, nurses, hospital managers, and public health experts. Evidence-based guidelines, microbiological data, local antibiograms, and institutional rules all help to shape activities.[9]

Core Principles of Antimicrobial Stewardship[10,11]

1. **Accurate Diagnosis of Infection:** Accurate diagnosis is an important feature of antimicrobial stewardship, as not all febrile diseases are caused by bacterial infections. This ensures that antibiotics are not used improperly for viral diseases such as influenza, the common cold, or viral pharyngitis. A complete diagnostic evaluation consists of multiple steps: acquiring a detailed patient history, completing a physical examination, conducting laboratory tests, engaging in culture and sensitivity testing, and using radiological imaging as needed. Collecting suitable microbiological specimens before beginning antibiotic treatment improves pathogen identification and enables targeted therapy. Furthermore, correct diagnoses are crucial in reducing unnecessary antibiotic exposure and slowing the spread of resistance.
2. **Appropriate Selection of Antimicrobial Agents:** Choosing the right antimicrobial drug is critical for optimal treatment while reducing resistance. The suspected or confirmed pathogen, infection site, sickness severity, local resistance patterns, and specific patient characteristics such as age, allergies, renal and hepatic function, pregnancy, and immunological state should all be considered when making a selection. To avoid needless microbial exposure and maintain normal flora, it is recommended to use narrow-spectrum antibiotics rather than broad-spectrum ones. While broad-spectrum covering may be required initially for severely ill individuals, treatment should then be customized based on microbiological results.
3. **Timely Initiation of Therapy:** Choosing the right antimicrobial drug is critical for optimal treatment while reducing resistance. The suspected or confirmed pathogen, infection site, sickness severity, local resistance patterns, and specific patient characteristics such as age, allergies, renal and hepatic function, pregnancy, and immunological state should all be considered when making a selection. To avoid needless microbial exposure and maintain normal flora, it is recommended to use narrow-spectrum antibiotics rather than broad-spectrum ones. While broad-spectrum covering may be required initially for severely ill individuals, treatment should then be customized based on microbiological results.
4. **Dose Optimization:** Dose optimization is essential for achieving adequate antimicrobial exposure at infection sites while minimizing toxicity and resistance. Key factors to examine include pharmacokinetic (PK) qualities, pharmacodynamic (PD) principles, organ function, infection severity, and patient demographics such as body weight and age. This optimization is especially important for severely ill patients and cases with resistant pathogens. Effective techniques include employing extended-infusion beta-lactams, high-dose treatments for severe infections, and modifying doses based on renal and hepatic function. The ultimate goal is to achieve maximum bacterial eradication while minimizing side effects and preventing resistance development.

5. **De-escalation of Therapy:** De-escalation in antimicrobial therapy is restricting the treatment based on microbiological culture and sensitivity findings following initial empirical broad-spectrum therapy. This strategy is critical for several reasons: it reduces resistance selection pressure, lowers toxicity concerns, lowers healthcare expenses, and aids in the preservation of natural microbiota. Furthermore, de-escalation is an important aspect of antimicrobial stewardship, necessitating regular appraisal of treatment options.
6. **Appropriate Duration of Therapy:** Excessive antibiotic medication adds greatly to the development of resistance and side effects. Antibiotic stewardship programs advocate for treatment durations based on evidence, taking into account the kind of illness, clinical response, microbiological findings, and host variables. According to research, shorter antibiotic courses can be just as effective as longer ones for a variety of illnesses, including community-acquired pneumonia, urinary tract infections, and intra-abdominal infections. Reducing the length of medication not only reduces antibiotic exposure but also lowers healthcare expenses.
7. **Intravenous-to-Oral Conversion:** Many patients can switch from intravenous (IV) to oral antibiotic therapy after they are clinically stable and able to tolerate oral medicine. This conversion requires hemodynamic stability, clinical improvement, a functional gastrointestinal tract, and the absence of severe sepsis. The advantages of transitioning to oral medicine are significant, including shorter hospital stays, cheaper treatment costs, fewer catheter-related problems, and improved patient comfort. Clinical pharmacists frequently play an important role in identifying potential candidates for the IV-to-oral conversion.
8. **Therapeutic Drug Monitoring (TDM):** Therapeutic drug monitoring (TDM) is the technique of measuring antimicrobial serum concentrations in order to maximize therapeutic efficacy while reducing toxicity. This procedure is critical for antimicrobials with restricted therapeutic indices, such as vancomycin, aminoglycosides, and voriconazole. TDM benefits include attaining therapeutic medication levels, reducing diseases such as nephrotoxicity and ototoxicity, increasing patient treatment results, and slowing the spread of antimicrobial resistance. TDM is especially important in critically ill patients as well as those with reduced renal or hepatic function.

COMMON CAUSES OF ANTIBIOTIC MISUSE

Antibiotic abuse has a significant impact on antimicrobial resistance (AMR), which is defined as incorrect antibiotic selection, dose, duration, or indication. This misuse takes place in a variety of contexts, including hospitals, outpatient clinics, community pharmacy, veterinary medicine, and agriculture. Such illogical habits exert selective pressure on microbes, resulting in the evolution of resistant strains and reducing the efficacy of current antimicrobial treatments.[12]

Antibiotic abuse leads to greater adverse medication responses, treatment failures, higher healthcare expenses, and higher mortality rates from resistant diseases. Globally, this misuse is driven by a variety of variables, including patient, physician, healthcare system, agricultural, and socioeconomic components. A thorough understanding of these contributing elements is required for the development of effective antimicrobial stewardship plans.[13]

1. **Use of Antibiotics for Viral Infections:** One of the most prominent causes of antibiotic abuse is the use of these prescriptions to treat viral infections such as the common cold, influenza, viral pharyngitis, acute bronchitis, and COVID-19 when there is no bacterial co-infection. Despite their ineffectiveness against viruses, antibiotics are frequently recommended due to diagnostic ambiguity, patient expectations, and concerns about potential secondary bacterial infections. This incorrect use can increase antibiotic resistance and alter the natural microbial flora.

Research indicates that a significant amount of outpatient antibiotic prescriptions, particularly for upper respiratory tract infections, are inappropriate, raising concerns regarding patient treatment methods.

2. **Empirical Broad-Spectrum Antibiotic Overuse:** Broad-spectrum antibiotics are routinely used empirically before determining the causal organism, which is crucial in critically unwell patients. However, continued or inappropriate use contributes significantly to antibiotic resistance. Carbapenems, third-generation cephalosporins, fluoroquinolones, and piperacillin-tazobactam are some of the most often used broad-spectrum antibiotics. Excessive use promotes the growth of multidrug-resistant organisms, including ESBL-producing Enterobacterales, carbapenem-resistant Enterobacterales (CRE), and multidrug-resistant Pseudomonas aeruginosa. Furthermore, not de-escalating medication after microbiological data are obtained exacerbates resistance problems.
3. **Self-Medication and Over-the-Counter Availability:** In many countries, the availability of antibiotics without a prescription has resulted in widespread self-medication behaviors among patients, who frequently rely on leftover drugs or buy antibiotics from pharmacies without contacting a healthcare professional. Key variables contributing to this phenomena include easy access to antibiotics, a lack of information about antimicrobial resistance, financial constraints, restricted healthcare access, and previous pleasant antibiotic experiences. However, self-medication can have a number of negative implications, including poor drug selection, wrong dose, insufficient treatment durations, and delays in recognizing major health concerns. This inappropriate usage of antibiotics exacerbates the problem of antimicrobial resistance, particularly in low- and middle-income nations.
4. **Incomplete Antibiotic Courses and Poor Patient Adherence:** Antibiotic resistance is greatly increased when prescription antibiotic medication is not followed. Despite persistent illnesses, patients frequently cease treatment too soon when their symptoms become better. Symptomatic improvement, side effects, medicine expenses, complicated dose schedules, and inadequate patient education are all contributing factors to poor adherence. The likelihood of recurring infections and the evolution of resistance increases when inadequate therapy fails to eradicate pathogens, allowing partially resistant organisms to survive. In order to guarantee therapy adherence and prevent the emergence of resistance, appropriate patient counseling is essential.
5. **Inappropriate Dose and Duration of Therapy:** Incorrect antibiotic dose and prolonged treatment durations are key contributors to overuse. Key problems include sub therapeutic dose, which may not effectively kill bacteria; excessive dosing, which can cause toxicity; and needlessly prolonged therapy, which increases the likelihood of bacterial resistance. Many infections can be efficiently treated with shorter antibiotic courses, but protracted therapy is still commonly used. This incorrect duration exposes microorganisms to selective pressure, resulting in severe effects such as Clostridioides difficile infection, nephrotoxicity, and hepatotoxicity. To address these issues, evidence-based guidelines advocate adjusting antibiotic dose and duration based on the kind of infection, individual patient variables, and pharmacokinetic/pharmacodynamic principles.
6. **Diagnostic Uncertainty and Lack of Rapid Diagnostic Tools:** Diagnostic ambiguity in clinical settings frequently leads to the over prescription of antibiotics as a preventative strategy, especially when discriminating between bacterial and viral diseases is difficult. Delays in culture results, restricted laboratory facilities, a lack of quick diagnostic tools, and poor microbiological support all contribute to this practice. In resource-constrained situations, the inability to undertake culture and sensitivity testing complicates targeted treatment, resulting to an increased reliance on empiric antibiotic therapy and a preference for broad-spectrum antibiotics.

PHARMACOTHERAPEUTIC STRATEGIES

Pharmacotherapeutic techniques are critical for antimicrobial stewardship because they optimize therapy to enhance clinical effectiveness while decreasing toxicity, side effects, treatment failure, and antimicrobial resistance (AMR). These tactics involve selecting, dosing, administering, and modifying medications based on patient-specific features, pathogen characteristics, and PK/PD principles.[14] Such approaches improve patient outcomes, lower healthcare costs, minimize hospital stays, and retain antibiotic potency. The emergence of multidrug-resistant pathogens such as MRSA, CRE, ESBL-producing organisms, and multidrug-resistant Pseudomonas aeruginosa has highlighted the need for improved pharmacotherapy. Antimicrobial stewardship initiatives promote sensible pharmacotherapeutic measures to reduce inappropriate antimicrobial usage and prevent resistance development.[15,16,17]

1. **Empirical Antimicrobial Therapy:** Empirical therapy is initiating antibiotic treatment before determining the specific pathogen and susceptibility, which is critical for treating severe infections such as sepsis, septic shock, meningitis, pneumonia, and febrile neutropenia. The selection of empirical antibiotics is influenced by a number of criteria, including the infection site, suspected microorganisms, local antibiogram data, sickness severity, patient history, past antimicrobial exposure, and the patient's immunological condition. Broad-spectrum antibiotics are usually delivered rapidly to severely ill patients in order to reduce mortality risks. However, the misuse or prolonged use of empirical therapy might result in increased antibiotic resistance. As a result, stewardship programs advocate for timely reevaluation and treatment adjustments as new microbiological information becomes available.
2. **Targeted (Definitive) Therapy:** Following pathogen identification, targeted therapy focuses on optimizing antimicrobial therapies using culture and sensitivity results. It stresses the use of the most effective narrow-spectrum medicines, which have several benefits, including reduced resistance selection pressure, lower toxicity, less disruption of normal flora, cheaper healthcare expenditures, and better clinical outcomes. For example, switching from carbapenems to ceftriaxone when susceptibility allows or utilizing penicillin for susceptible Streptococcus infections are examples of this strategy. Targeted therapy is essential to antimicrobial stewardship efforts.
3. **De-escalation Therapy:** De-escalation in antimicrobial therapy entails switching from broad-spectrum to narrow-spectrum treatment after getting microbiological results and confirming clinical improvement. This technique has several benefits: it decreases needless antimicrobial exposure, slows the emergence of resistance organisms, reduces the likelihood of adverse medication reactions, and lowers treatment costs. De-escalation techniques may include discontinuing combination therapy, reducing the antibiotic spectrum, or eliminating unneeded medicines. One example is switching from meropenem to cefazolin after diagnosing methicillin-resistant Staphylococcus aureus (MSSA). Regular daily evaluations of antimicrobial therapy are essential for optimal de-escalation.
4. **Dose Optimization:** PK/PD adjustment is critical for increasing antimicrobial efficacy while minimizing toxicity and resistance. Pharmacokinetics (PK) studies the absorption, distribution, metabolism, and elimination of medications, whereas pharmacodynamics (PD) investigates the link between drug concentration and antibacterial effect. Antibiotics are classified into two types: time-dependent antibiotics, which require drug concentrations above the minimum inhibitory concentration (MIC) for efficacy, such as beta-lactams and vancomycin, necessitating strategies such as frequent dosing, extended infusion, and continuous infusion. The second group, Concentration-Dependent Antibiotics, is based on obtaining high peak concentrations for efficacy, as demonstrated by aminoglycosides and fluoroquinolones, which employ tactics such as high-dose extended interval

administration. Optimizing PK/PD parameters improves bacterial kills while also reducing the establishment of resistance.

5. **Combination Antimicrobial Therapy:** Combination therapy is the simultaneous use of two or more antimicrobial medicines.

Indications include: Severe infections.
Polymicrobial infections.

Tuberculosis

Prevention of resistance.

Synergistic activity.

Benefits:

broader antimicrobial coverage

Synergistic bacterial killing.

Prevention of resistance emergence.

Antitubercular multidrug regimens.

Vancomycin plus piperacillin/tazobactam in severe sepsis

However, needless combination therapy increases toxicity, cost, and the danger of superinfection. Thus, stewardship initiatives stress the use of reasonable combinations.

6. **Therapeutic Drug Monitoring (TDM):** Serum antimicrobial concentrations are measured to maximize efficacy while minimizing toxicity.

TDM is especially crucial for medications like:

Narrow therapeutic index.

Variable pharmacokinetics.

Significant toxicity potential.

Common medicines that require TDM:

Vancomycin

Aminoglycosides

Voriconazole

Benefits:

Prevent nephrotoxicity and ototoxicity.

Reach therapeutic concentrations.

Reduce treatment failures.

Improve patient outcomes.

TDM is particularly beneficial for critically ill patients and those with renal impairment.

STEWARDSHIPINTERVENTIONS

Antimicrobial stewardship interventions are integrated efforts aimed at optimizing antimicrobial use, improving patient outcomes, reducing antimicrobial resistance (AMR), minimizing adverse medication events, and lowering healthcare costs. These treatments lay the groundwork for antimicrobial stewardship programs (ASPs) in hospitals, outpatient clinics, long-term care facilities, and community healthcare systems. Effective stewardship interventions ensure that antimicrobial drugs are only provided when absolutely necessary, and that the appropriate medication, dose, route, and duration are chosen based on evidence-based recommendations and microbiological data.[18]

Stewardship interventions are broadly classified into:

Core interventions

Supplemental interventions.

Diagnostic Interventions

Educational interventions

Infection Prevention Strategies

Technology-based interventions.

These strategies necessitate coordination among infectious disease physicians, clinical pharmacists, microbiologists, infection control specialists, nurses, and hospital administrators.[19]

1. Prospective Audit and Feedback

Prospective auditing with action and feedback is one of the most successful antimicrobial stewardship practices. In this strategy, antimicrobial prescriptions are reviewed after beginning and prescribers are given recommendations for optimizing or modifying therapy.

The stewardship team evaluates: appropriateness of antimicrobial selection.

Dose and Duration

Route of Administration

Need for de-escalation.

Culture and susceptibility results

Recommendations might include

The discontinuation of unneeded antibiotics

Switching to narrow-spectrum therapies

Dose optimization

IV to oral conversion

Benefits:

Improved antimicrobial appropriateness.

Reduced broad-spectrum antibiotic usage.

Lower resistance rates.

Enhanced physician education.

This technique maintains clinician autonomy while encouraging evidence-based prescribing practices.

2. Formulary Restriction and Preauthorization

Formulary restrictions restrict the use of certain antimicrobial medicines to recognized indications or need prior authorization before use. This intervention is typically used for:

Carbapenems

Colistin, Linezolid
Daptomycin

Novel broad-spectrum agents.

Preauthorization usually requires approval from:

Infectious disease experts

Clinical Pharmacists

Stewardship Committees

Advantages:

Reduces inappropriate usage of broad-spectrum antibiotics.

controls antimicrobial expenditure.

Preserves last resort antibiotics.

Reduces resistance development.

However, if not handled properly, excessive limitation may cause therapeutic initiation to be delayed in critically ill patients.

3. Development and Implementation of Clinical Guidelines

Evidence-based antimicrobial therapy guidelines help to standardize prescribing methods and increase therapeutic consistency.

Guidelines are based upon:

National recommendations.

Local antibiograms.

Resistance Patterns

Institutional Policies

Infection-specific procedures.

Common stewardship guidelines address the following:

Community-acquired pneumonia.

Urinary tract infections.

Sepsis

Surgical prophylaxis

Skin and soft tissue infections.

Benefits:

reduces improper prescribing variation.

Increases adherence to excellent practices.

Improves patient safety.

promotes tailored therapy.

Institution-specific criteria are especially relevant because resistance patterns differ spatially.

4. Antimicrobial Time-Outs

Antimicrobial time-outs include reevaluating ongoing antibiotic medication after 48-72 hours of start.

During the reassessment, professionals evaluate:

Clinical reaction.

Cultural and sensitivity reports

Need for ongoing therapy

Opportunities for De-escalation

appropriate duration of treatment.

Questions under consideration include:

Is the infection confirmed?

Can therapy be narrowed?

Can antibiotics be discontinued?

Is it possible to convert from intravenous to oral?

Time-outs encourage regular therapeutic reviews and avoid inappropriate antibiotic use.

5. Dose Optimization and PK/PD-Based Dosing

Pharmacokinetic/pharmacodynamic (PK/PD) optimization is emphasized in stewardship programs in order to optimize efficacy while reducing toxicity.

Strategies include:

Extended-infusion beta-lactams

Continuous infusion regimens

Weight-based dosage.

Renal dosage modifications

Hepatic dose adjustments

PK/PD optimization is very significant in Critically sick patients Resistant infections

Patients having altered drug clearance.

Dose adjustment increases bacterial eradication while reducing the establishment of resistance.

6. Rapid Diagnostic Testing

Rapid diagnostic methods enhance pathogen detection and enable early targeted therapy.

Examples include:

Polymerase Chain Reaction (PCR)

MALDI-TOF Mass Spectrometry

Multiplex Molecular Panels

Rapid blood culture identification systems.

Benefits:

Faster pathogen detection.

Reduced empirical broad-spectrum use.

Earlier deescalation
improved patient outcomes.

Rapid diagnosis, paired with stewardship efforts, greatly minimize improper antibiotic use.

ROLE OF CLINICAL PHARMACIST

Clinical pharmacists play critical roles in antimicrobial stewardship programs (ASPs), which focus on the appropriate use of antimicrobial medicines to improve patient outcomes, reduce antimicrobial resistance (AMR), limit adverse medication effects, and lower healthcare costs. Their understanding of pharmacology, pharmacokinetics, pharmacodynamics, drug interactions, and medication safety enables them to considerably improve antimicrobial therapy.[15] Clinical pharmacists are now valued members of interdisciplinary ASP teams, working with physicians, microbiologists, infection control experts, nurses, and hospital administrators(. The emergence of multidrug-resistant pathogens, as well as the growing complexity of antimicrobial therapies, have expanded clinical pharmacists' roles in both inpatient and outpatient care. Interventions led by pharmacists have been shown to improve adherence to guidelines, reduce inappropriate antibiotic prescriptions, lower resistance rates, and shorten hospital stays(20).

1. Optimization of Antimicrobial Therapy

Clinical pharmacists' key tasks include optimizing antimicrobial therapy to guarantee safe, effective, and evidence-based treatment.

This includes: Choosing the most suitable antibacterial agent Selecting the optimum dose Determining the optimum route of administration Ensure the optimum period of therapy.

Pharmacists evaluate:
Type and severity of infection.
Cultural and sensitivity results Patient-specific factors.
Local resistance patterns
Organ function.
Drug Allergies

They help to ensure that antimicrobial therapy adheres to institutional rules and antimicrobial stewardship principles. Appropriate optimization increases therapeutic efficacy while minimizing resistance development.

2. Participation in Antimicrobial Stewardship Programs (ASPs)

Important members of ASPs, clinical pharmacists take an active part in stewardship initiatives like:

Prospective evaluation and comments Programs for antimicrobial restriction Management of formulary Creation of recommendations for treatment Keeping an eye on antimicrobial usage Healthcare professionals' education Every day, pharmacists examine antibiotic prescriptions and suggest changes when treatment is ineffective or inappropriate.

Pharmacist interventions include, for instance: Broad-spectrum treatment de-escalation Stopping the use of needless antibiotics.

Modification of dosage Conversion from IV to oral Preventing redundant use of antibiotics Research has demonstrated that the involvement of pharmacists considerably lowers the inappropriate use of antibiotics and enhances stewardship policy compliance.

3. Identification and Prevention of Drug Interactions and Adverse Drug

Clinical chemists keep an eye out for possible side effects from antimicrobial therapy.

Interactions between drugs
Interactions between drugs and food
Reactions to allergies
Toxicities of the organs
Adverse drug reactions
Examples consist of:
QT prolongation caused by macrolides and fluoroquinolones
Vancomycin and aminoglycoside-induced nephrotoxicity
Hepatotoxicity from antitubercular medications
Linezolid-induced bone marrow suppression
Pharmacists monitor test values and suggest safer substitutes to assist reduce medication-related problems.

4. Intravenous-to-Oral (IV-to-PO) Conversion

Clinical chemists determine which patients can switch from intravenous to oral antibiotic medication.

Among the criteria are:
Clinical enhancement
Stability of hemodynamics
Tolerance for oral drugs
Gastrointestinal tract function
IV-to-oral conversion benefits include: shorter hospital stays
Reduced medical expenses
decreased infections linked to catheters
Enhanced comfort for patients

IV-to-PO conversion programs run by pharmacists greatly increase the effectiveness of antibiotic use.

5. Participation in Ward Rounds and Clinical Decision-Making

Clinical pharmacists work with doctors to make therapeutic decisions and actively participate in multidisciplinary ward rounds.

Pharmacists provide recommendations about the following during rounds:
Selection of antimicrobials
Modifications to dosage
interpretation of culture

Observing parameters
Therapy duration
Compatibility of drugs

Direct pharmacist participation boosts patient outcomes, decreases prescription errors, and improves communication. Their involvement is particularly beneficial in wards for infectious diseases and intensive care units.

6. Development of Institutional Antimicrobial Guidelines

Institutional antimicrobial policy and treatment guidelines are prepared and implemented in part by clinical pharmacists.

Among the responsibilities are:
reating procedures for antibiotics
Keeping institutional formularies current
Examining local antibiograms
Putting restrictions in place
Standardizing recommendations for treatment

These recommendations lessen needless variation in the use of antibiotics and help guarantee evidence-based prescribing.

7. Surveillance and Monitoring of Antimicrobial Use

Clinical pharmacists keep an eye on changes in antibiotic resistance and usage in medical facilities.

Typical activities consist of:
Monitoring the use of antibiotics
Keeping an eye on resistance patterns
Antibiogram preparation
Examining prescriptions for antibiotics
Assessing stewardship results
Among the metrics tracked are:
DDD, or defined daily dosage
Therapy days (DOT)
Rates of resistance
Rates of infection with Clostridium difficile
Surveillance facilitates stewardship initiatives and aids in the identification of improper prescribing practices.

MONITORING AND OUTCOME ASSESSMENT

Monitoring and Evaluation of Antimicrobial Stewardship Results.

Antimicrobial stewardship programs (ASPs) must include monitoring and outcome assessment. These procedures assess stewardship programs' efficacy, safety, quality, and effects on antimicrobial usage, antimicrobial resistance (AMR), patient outcomes, and healthcare expenses. Healthcare organizations can detect improper antimicrobial practices, monitor resistance patterns, evaluate stewardship policy compliance, and put corrective actions in place to enhance antimicrobial consumption through continuous monitoring. Determining whether stewardship interventions meet their intended clinical and financial objectives is another benefit of outcome assessment. (CDC) Multidisciplinary cooperation between clinical pharmacists, infectious disease specialists, microbiologists, infection control teams, epidemiologists, and hospital administrators is necessary for effective monitoring systems. In community healthcare systems, long-term care facilities, outpatient settings, and hospitals, monitoring and assessment are crucial. Effective outcome evaluation promotes evidence-based decision-making and fortifies antimicrobial stewardship initiatives.[20]

Objectives of Monitoring and Outcome Assessment

Among the main goals are:

Assessing the suitability of prescribing antibiotics

Tracking the use of antibiotics

Finding patterns of resistance

Evaluating patient results

Recognizing negative drug effects

Assessing the success of stewardship initiatives

Lowering infections linked to healthcare

Assessing the economic impact

Ensuring adherence to rules and regulations

Antimicrobial therapy is optimized through ongoing evaluation, which also reduces the emergence of resistance and needless antimicrobial exposure.[21]

1. Monitoring Antimicrobial Utilization

One of the main purposes of stewardship programs is to monitor the use of antibiotics. It aids in spotting trends of overuse of antibiotics and improper prescription practices.

Typical techniques include:

a. DDD, or Defined Daily Dose

The average maintenance dose of a medication taken daily for its primary indication in adults is known as the defined daily dose.

Advantages

Measurement that is standardized enables comparison between regions and hospitals. Beneficial for research on surveillance.

Limitations

In pediatric populations, less accurate does not take dosage modifications into account.

Globally, the WHO Anatomical Therapeutic Chemical (ATC)/DDD system is extensively utilized.

b. Days of Therapy (DOT)

Regardless of dosage, DOT counts the number of days a patient takes a particular antibiotic.

Advantages

More precise than DDD helpful in situations involving renal dosage adjustments and pediatrics more accurately depicts exposure to antibiotics For instance, DOT = 5 if a patient takes ceftriaxone for five days.

Stewardship surveillance programs frequently use DOT.

c. Length of Therapy (LOT)

Regardless of the amount of antibiotics used concurrently, LOT refers to the entire time of antimicrobial treatment.

This measure aids in assessing:

Extended treatment

Antimicrobial coverage in duplicate

Optimization of treatment

2. Monitoring Appropriateness of Antimicrobial Prescribing

Stewardship teams use institutional and evidence-based criteria to determine if antibiotic prescriptions are acceptable.

Among the evaluation criteria are:

The right indication

The right choice of antimicrobials

The right dosage

The appropriate administration route

The right amount of time

Possibilities for de-escalation

Results of adherence to culture

Techniques employed:

Prospective evaluation and comments

Review of prescriptions

Surveys of point prevalence

Audits of charts

Monitoring the appropriateness of prescriptions enhances adherence to guidelines and decreases the unnecessary use of antibiotics.

3. Monitoring Antimicrobial Resistance Patterns

Understanding the epidemiology of resistant organisms and directing empirical therapy depend on tracking resistance trends.

Typical organisms under observation are:

Methicillin-resistant MRSA, or Staphylococcus aureus

Enterococci resistant to vancomycin (VRE)

Enterobacterales resistant to carbapenem (CRE)

Organisms that produce ESBL

Pseudomonas aeruginosa that is resistant to multiple drugs

Techniques consist of:

Sensitivity monitoring and culture

Antibiograms in hospitals

Systems of national surveillance

Testing for molecular resistance

Antibiograms help empirical antibiotic selection by summarizing patterns of local susceptibility. Treatment guidelines and stewardship rules are updated through routine resistance surveillance.

4. Monitoring Clostridioides difficile Infection (CDI)

One of the main risk factors for Clostridium difficile infection is overuse of antibiotics.

Stewardship initiatives keep an eye on:

Incidence rates of CDI

Use of high-risk antibiotics

Outbreaks of infections

CDI incidence are considerably reduced by limiting needless exposure to broad-spectrum antibiotics. Typical high-risk antibiotics consist of:

Clindamycin

Fluoroquinolones

Cephalosporins

Carbapenems

CDI rates are crucial measures of the efficacy of stewardship.

5. Process Measures in Stewardship Programs

Process indicators evaluate how well stewardship initiatives are implemented and adhered to.

Examples consist of: adherence to institutional policies percentage of prescriptions for antibiotics that were examined.

The percentage of pharmacist suggestions that are accepted

De-escalation intervention percentage

IV-to-oral conversion rates

Indication and duration documentation

These metrics aid in assessing stewardship performance and pinpointing areas in need of development.

6. Infection Prevention and Control Indicators

To keep an eye on healthcare-associated infections (HAIs), stewardship programs work with infection prevention teams.

Key indicators consist of:

Bloodstream infections linked to central lines (CLABSI)

Urinary tract infections linked to catheter use (CAUTI)

Infections at the surgical site (SSI)
Pneumonia linked to ventilators (VAP)
Antimicrobial use and the burden of AMR are reduced when HAIs are reduced.

CHALLENGES IN MONITORING AND OUTCOME ASSESSMENT

Typical difficulties consist of:
Insufficient infrastructure for microbiology
Insufficient electronic health systems
Insufficiently skilled staff
Inadequate techniques for gathering data
Insufficient funds
Inconsistent methods of surveillance

These issues are especially important in nations with low and moderate incomes. For efficient monitoring, stewardship infrastructure and laboratory capacity must be strengthened.[22]

Challenges in Implementation

Implementing Antimicrobial Stewardship Programs: Difficulties

Combating antimicrobial resistance (AMR), maximizing antibiotic use, enhancing patient outcomes, and lowering healthcare costs all depend on the implementation of antimicrobial stewardship programs (ASPs). Even though stewardship programs have been shown to be beneficial, many healthcare organizations encounter considerable obstacles when trying to adopt and maintain efficient antimicrobial stewardship procedures. These issues are complex and differ between healthcare environments, especially between high-income and low- and middle-income countries (LMICs). Implementing stewardship is severely hampered by elements including scarce resources, bad infrastructure, a lack of qualified staff, diagnostic constraints, subpar regulatory frameworks, and ignorance.

Stewardship efforts are made more difficult by the complexity of prescription antibiotics, the rise in multidrug-resistant pathogens, and differences in healthcare systems. Developing successful plans to improve antimicrobial stewardship worldwide requires an understanding of these implementation challenges.[23]

1. Lack of Awareness and Education

Inadequate knowledge and comprehension of antimicrobial resistance and stewardship principles among healthcare professionals and the general public is one of the main obstacles to the implementation of antimicrobial stewardship.

Issues pertaining to healthcare providers include:
Insufficient understanding of the concepts of antimicrobial stewardship
Insufficient instruction in logical prescription
Inadequate knowledge of resistance mechanisms
Insufficient knowledge of institutional policies
Issues pertaining to the public include:
False beliefs regarding antibiotics
Antibiotic demand for viral illnesses

Self-medication behaviors

Inadequate compliance with recommended treatment

Inadequate education results in poor adherence to stewardship initiatives and incorrect prescribing. Therefore, public awareness campaigns and ongoing professional development are crucial elements of a successful ASP deployment.

2. Shortage of Trained Healthcare Personnel

Multidisciplinary cooperation involving the following is necessary for effective ASPs:

Physicians who treat infectious diseases

Pharmacists in clinical practice

Microbiologists

Experts in infection control

Nurses and epidemiologists

Many healthcare facilities, especially those in LMICs, lack staff with the necessary training to set up and run stewardship programs.

Typical issues facing the workforce include:

Lack of experts in infectious diseases

Restricted clinical pharmacy services

Inadequate knowledge of microbiology

Overworked medical personnel

Absence of programs for stewardship training

The efficacy of stewardship measures is diminished when antimicrobial prescribing is not adequately supervised by trained staff.

3. Limited Microbiology and Diagnostic Facilities

Targeted antibiotic therapy and de-escalation depend on accurate diagnosis and microbiological confirmation.

But a lot of institutions have to deal with:

Absence of labs for microbiology

Culture reports that are delayed

Testing for limited susceptibility

Inadequate facilities for laboratories

Absence of quick diagnostic tools

Because of this, doctors often administer broad-spectrum antibiotics on an empirical basis without consulting microbiologists. This leads to the overuse of antibiotics and the emergence of resistance.

One of the biggest obstacles to successful stewardship adoption in environments with limited resources is inadequate diagnostic capability.

4. Inadequate Financial Resources

ASP implementation necessitates a substantial cost outlay for:

Infrastructure for laboratories

Systems for information technology

Personnel with training

Programs for surveillance

Activities for education

Quick diagnostic instruments

Due to financial constraints, many hospitals—particularly those with limited resources—prioritize urgent clinical needs over stewardship initiatives.

Budget constraints frequently lead to:

Insufficient personnel

Absence of monitoring systems

Inadequate stewardship oversight restricted availability of diagnostics.

Inadequate funding can seriously impair the sustainability and efficacy of stewardship. ASP implementation necessitates a substantial cost outlay for:

Infrastructure for laboratories

Systems for information technology

Personnel with training

Programs for surveillance

Activities for education

Quick diagnostic instruments

Due to financial constraints, many hospitals—particularly those with limited resources—prioritize urgent clinical needs over stewardship initiatives.

Budget constraints frequently lead to:

Insufficient personnel

Absence of monitoring systems

Inadequate stewardship oversight

restricted availability of diagnostics

Inadequate funding can seriously impair the sustainability and efficacy of stewardship.

5. Lack of Institutional Support and Leadership Commitment

Implementing ASP successfully requires strong administrative commitment.

Among the difficulties are:

Hospital administration's lack of support

Absence of stewardship guidelines

Inadequate stewardship activity prioritization

Insufficient methods of accountability

Inadequate distribution of resources

Stewardship teams may not have the power to implement antimicrobial policy and interventions without leadership backing. Building infrastructure for sustainable stewardship requires institutional commitment.

FUTURE PERSPECTIVES

Antimicrobial Stewardship and Antimicrobial Resistance Management: Prospects for the Future

One of the biggest risks to global public health in the twenty-first century is antimicrobial resistance (AMR). The fast growth of multidrug-resistant organisms continues to pose a challenge to healthcare systems around the world, despite advancements in antimicrobial stewardship programs (ASPs), infection control techniques, and global surveillance networks. In order to maintain antimicrobial efficacy for future generations, future perspectives on antimicrobial stewardship center on enhancing international cooperation, incorporating cutting-edge technologies, enhancing diagnostics, creating innovative treatments, extending stewardship to all healthcare settings, and implementing a One Health strategy.

In order to maximize the use of antibiotics and prevent the emergence of resistance, future antimicrobial stewardship initiatives will depend more and more on precision medicine, artificial intelligence, genomic technologies, quick diagnostics, and interdisciplinary cooperation. Coordinated efforts from the fields of human health, veterinary medicine, agriculture, environmental health, public policy, and pharmaceutical research are necessary to effectively address AMR.[24]

1. Expansion of Precision Antimicrobial Therapy

An developing strategy called precision antimicrobial therapy optimizes antimicrobial treatment by utilizing unique patient and pathogen data.

This tactic entails:
Pathogen genomic analysis
Pharmacogenomics
Therapy guided by biomarkers
Customized PK/PD (pharmacokinetic/pharmacodynamic) dosage
Immune profile of the host
The goals of precision therapy are to:
Boost the effectiveness of treatment
Reduce needless exposure to antibiotics
Cut down on toxicity
Stop the rise of resistance

Future highly focused antimicrobial therapy is anticipated to be made possible by developments in genome sequencing and molecular diagnostics.

2. Artificial Intelligence and Machine Learning in Stewardship

Programs for antimicrobial stewardship are progressively incorporating machine learning and artificial intelligence (AI).

Among the possible uses are:

Antimicrobial resistance pattern prediction

Recognizing improper prescriptions

Endorsing the choice of empirical therapy

Alerts for automated stewardship

Optimizing the dosage of antibiotics

Forecasting the occurrence of infections

Large datasets may be quickly analyzed by AI-driven clinical decision support systems, which can help physicians make evidence-based prescription decisions.

Future AI applications could greatly increase the effectiveness of stewardship, the precision of surveillance, and the capacity to forecast resistance.

3. Rapid Diagnostic Technologies

Rapid diagnostic tools will be essential for early pathogen identification and resistance detection in future stewardship initiatives.

Among the emerging technologies are:

PCR, or multiplex polymerase chain reaction

Sequencing the entire genome

Mass spectrometry using MALDI-TOF

CRISPR-based diagnostics

Molecular testing at the point of care

sequencing of metagenomes

Advantages consist of:

Quicker diagnosis

Early-stage targeted treatment

Decreased use of empirical broad-spectrum antibiotics

Better de-escalation

Improved results for patients

Future healthcare systems should make rapid diagnostics more broadly available and reasonably priced.

4. Development of Novel Antimicrobial Agents

New antimicrobial medicines are desperately needed as multidrug-resistant pathogens proliferate.

Future studies concentrate on:

Innovative antibiotics

Peptides with antimicrobial properties

Treatment using bacteriophages

Antibodies that are monoclonal

Nanoparticles with antimicrobial properties

Antiviral agents

Recently, a number of more advanced antimicrobial drugs have been created to combat resistant Gram-negative infections, such as:

Cefiderocol

Ceftazidime-avibactam

Meropenem-vaborbactam

Cilastatin, relebactam, and imipenem

To overcome upcoming resistance issues, funding for antimicrobial research and development must be sustained.

5. Bacteriophage Therapy

The use of bacteriophage therapy as a substitute or supplement to antibiotics is becoming more popular.

Viruses known as bacteriophages can specifically infect bacteria and target organisms that are resistant to drugs.

Benefits consist of:

Excellent specificity

less disturbance of the typical microbiota

Action against germs that are resistant

Possible penetration of biofilms

Among the difficulties are:

Regulatory clearance

Uniformity

Resistance to phages

Insufficient evidence from clinical trials

Bacteriophage therapy may prove to be a significant treatment option for resistant infections in the future.

6. Strengthening Global Surveillance Systems

Stronger international surveillance mechanisms are necessary for monitoring future AMR control initiatives.

Trends of resistance

Use of antimicrobials

Resistant pathogens that are emerging

Identification of outbreaks

It is anticipated that initiatives like the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) will continue to grow.

Enhanced monitoring will be beneficial:

Direct empirical treatment

Educate public health policies

Identify new patterns of resistance

Assess stewardship initiatives

Effective AMR containment depends on international cooperation and global data sharing.

CONCLUSION

Antimicrobial resistance (AMR) is a growing global health threat driven largely by the inappropriate and excessive use of antimicrobial agents. Antimicrobial Stewardship Programs (ASPs) play a crucial role in promoting the rational use of antibiotics through evidence-based strategies such as appropriate antimicrobial selection, dose optimization, de-escalation of therapy, therapeutic drug monitoring, and adherence to clinical guidelines. These interventions help improve patient outcomes, reduce adverse drug reactions, minimize healthcare costs, and slow the emergence of resistant microorganisms. Clinical pharmacists are key contributors to stewardship efforts through medication review, optimization of antimicrobial therapy, monitoring for drug-related problems, education of healthcare professionals and patients, and participation in multidisciplinary healthcare teams. Despite challenges such as limited resources, inadequate diagnostic facilities, and lack of awareness, continued investment in stewardship initiatives, rapid diagnostic technologies, surveillance systems, and innovative therapeutic approaches is essential. Strengthening antimicrobial stewardship through collaborative and patient-centered practices is vital to preserving the effectiveness of existing antimicrobials and combating the global burden of antimicrobial resistance.

REFERENCES

1. World Health Organization. Antimicrobial resistance. Geneva: WHO, 2023.
2. Dyar OJ, Huttner B, Schouten J, Pulcini C. What is antimicrobial stewardship? Clin Microbiol Infect, 2017; 23(11): 793–798.
3. Centers for Disease Control and Prevention. About Antimicrobial Resistance. Atlanta: CDC, 2025.
4. World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS). Geneva: WHO, 2025.
5. Infectious Diseases Society of America. Guidance on Treatment of Antimicrobial Resistant Gram-Negative Infections. IDSA, 2024.
6. Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet, 2022; 399(10325): 629–655.
7. World Bank. Drug-resistant infections: a threat to our economic future. Washington DC: World Bank, 2017.
8. Centers for Disease Control and Prevention. Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta: CDC, 2025.
9. World Health Organization. WHO bacterial priority pathogens list 2024. Geneva: WHO, 2024
10. Surviving Sepsis Campaign. International Guidelines for Management of Sepsis and Septic Shock.
11. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States. Atlanta: CDC, 2024
12. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial resistant Gram-negative infections [Internet]. Arlington (VA): Infectious Diseases Society of America, 2024 [cited 2026 May 7].

13. Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet, 2016; 387(10014): 176–187
14. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis, 1998; 26(1): 1–10.
15. Roberts JA, Abdul-Aziz MH, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, et al. Continuous versus intermittent beta-lactam infusion in severe sepsis. Clin Infect Dis, 2016; 52(Suppl 7): S397–S407.
16. Society for Healthcare Epidemiology of America. Antimicrobial stewardship resources [Internet]. Arlington (VA): SHEA, 2025 [cited 2026 May 7].
17. Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Lancet Infect Dis, 2018; 18(1): 95–107.
18. Centers for Disease Control and Prevention. Core elements of hospital antibiotic stewardship programs [Internet]. Atlanta (GA): CDC; 2025 [cited 2026 May 7]. Roberts JA, Abdul-Aziz MH, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, et al. Continuous versus intermittent beta-lactam infusion in severe sepsis. Clin Infect Dis, 2016; 52(Suppl 7): S397–S407.
19. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis, 2007; 44(2): 159–177.
20. Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and Society for Healthcare Epidemiology of America. Clin Infect Dis, 2016; 62(10): e51–e77.
21. Infectious Diseases Society of America. Guidance on treatment of antimicrobial resistant Gram-negative infections [Internet]. Arlington (VA): IDSA; 2024 [cited 2026 May 7].
22. Nature Reviews Microbiology. Precision antimicrobial therapy and future directions [Internet]. London: Nature Publishing Group; 2022 [cited 2026 May 7].
23. Centers for Disease Control and Prevention. Antibiotic use in the community [Internet]. Atlanta (GA): CDC; 2025 [cited 2026 May 7].
24. World Health Organization. Global action plan on antimicrobial resistance [Internet]. Geneva: WHO; 2015 [cited 2026 May 7].